EdenRed

CMD at first sight: Weak near-term objectives overshadow

04/11/25 -"Edenred’s share price saw a decline of up to 10% after the CMD publication, likely due to market scepticism regarding near-term execution and the prolonged effects of regulatory changes in ..."

PDF page sample
Pages
53
Language
English
Published on
04/11/25
Download
You may also be interested by these reports :
04/11/25
Edenred’s share price saw a decline of up to 10% after the CMD publication, likely due to market scepticism regarding near-term execution and the ...
03/11/25
Our EPS for 2025 and 2026 suffered from the integration of Imerys model update following Q2 results, which came in below our analyst expectations. ...
03/11/25
GBL has announced a (less surprising) portfolio simplification with significant monetisation of its indirect private capital assets (GBL Capital). ...
31/10/25
Q3 revenues came in better than expected, but the company guided for a reduced range of growth for 2026. Yet several items underscore the ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO